Hims & Hers Health (NYSE: HIMS), the telehealth company famous for selling Ozempic lookalikes over the internet, is tumbling ...

Telehealth company Hims & Hers Health (NYSE:HIMS) fell short of the market’s revenue expectations in Q2 CY2025, but sales ...

Hims’ second-quarter revenue fell 7% from a quarter ago. The decline goes beyond weakness in its GLP-1 weight-loss business.

Hims & Hers Health Inc (HIMS) reports a 73% revenue surge and strategic acquisitions, while navigating challenges in cash ...

Hims & Hers ...

Hims & Hers Health (HIMS) stock falls after reporting lower Q2 revenues. Analysts caution about near-term challenges, ...

Hims & Hers Health Inc. (NYSE: HIMS) plunged 13.1% in Tuesday pre-market after the digital health company reported ...

The telehealth-consultation platform posted an increase in profit and revenue for the second quarter on growth in subscribers ...

Hims & Hers Health's Q2 revenue miss and decelerating growth triggered a stock drop. Find out why I maintain a 'Buy' rating ...

Hims & Hers Health, a telehealth platform that sells knock offs of popular weight loss drugs, sank in after-hours trading ...

Hims & Hers stock (NASDAQ: HIMS) fell approximately 13% in after-hours trading following Q2 results that demonstrated strong ...

Now, it’s worth noting Stock Advisor’s total average return is 1,039% — a market-crushing outperformance compared to 181 % for the S&P 500. Don’t miss out on the latest top 10 list, available when you ...